|9 Months Ended|
Sep. 30, 2022
|Subsequent Events [Abstract]|
12. Subsequent Events
The Company sold 2,821,315 shares of its common stock under its ATM Facility pursuant to the Sales Agreement with Jefferies during the period from October 1, 2022 through November 7, 2022. Net proceeds were $15.3 million, after deducting issuance costs.
The Company sold 1,033,434 shares of Vaxcyte common stock at their fair market value during the period from October 1, 2022 through November 7, 2022, for net proceeds of $28.1 million.
No definition available.
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef